Epcoritamab + R2 Regimen and Responses in Patients With High-Risk Follicular Lymphoma, Regardless of POD24 Status

Lunenburg Lymphoma Phase I II

doi:10.1200/JCO.2023.41.16_suppl.7506

Epcoritamab + R2 Regimen and Responses in Patients With High-Risk Follicular Lymphoma, Regardless of POD24 Status

Lunenburg Lymphoma Phase I II

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	41
Issue number	16
Early online date	31 May 2023
DOIs	https://doi.org/10.1200/JCO.2023.41.16_suppl.7506
Publication status	Published - 1 Jun 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2023.41.16_suppl.7506

Cite this

@article{b28e6da17d2543c9b884585bc193cf1b,

title = "Epcoritamab + R2 Regimen and Responses in Patients With High-Risk Follicular Lymphoma, Regardless of POD24 Status",

author = "{Lunenburg Lymphoma Phase I II} and R Merryman and D Belada and A Sureda and S Lepp{\"a} and JSP Vermaat and H Holte and M Hutchings and P Lugtenburg and {de Vos}, S and P Abrisqueta and M Nijland and JH Christensen and BE Wahlin and KM Linton and LW Wang and A Abbas and A Rana and S Quadri and L Falchi",

year = "2023",

month = jun,

day = "1",

doi = "10.1200/JCO.2023.41.16_suppl.7506",

language = "English",

volume = "41",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "16",

}

TY - JOUR

T1 - Epcoritamab + R2 Regimen and Responses in Patients With High-Risk Follicular Lymphoma, Regardless of POD24 Status

AU - Lunenburg Lymphoma Phase I II

AU - Merryman, R

AU - Belada, D

AU - Sureda, A

AU - Leppä, S

AU - Vermaat, JSP

AU - Holte, H

AU - Hutchings, M

AU - Lugtenburg, P

AU - de Vos, S

AU - Abrisqueta, P

AU - Nijland, M

AU - Christensen, JH

AU - Wahlin, BE

AU - Linton, KM

AU - Wang, LW

AU - Abbas, A

AU - Rana, A

AU - Quadri, S

AU - Falchi, L

PY - 2023/6/1

Y1 - 2023/6/1

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:001053772003450&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1200/JCO.2023.41.16_suppl.7506

DO - 10.1200/JCO.2023.41.16_suppl.7506

M3 - Meeting Abstract

SN - 0732-183X

VL - 41

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16

ER -

Epcoritamab + R2 Regimen and Responses in Patients With High-Risk Follicular Lymphoma, Regardless of POD24 Status

UN SDGs

Access to Document

Other files and links

Cite this